• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Prothena Corporation plc

    8/8/25 4:30:29 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTA alert in real time by email
    S-8 1 forms-8aug2025.htm FORM S-8 Document

    As filed with the Securities and Exchange Commission on August 8, 2025
    Registration No. 333-
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM S-8 
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
     
    Prothena Corporation Public Limited Company
    (Exact name of registrant as specified in its charter)
     
     
     
    Ireland98-1111119
    (State or other jurisdiction of
    incorporation or organization)
    (IRS Employer
    Identification No.)
    77 Sir John Rogerson’s Quay, Block C
    Grand Canal Docklands
    Dublin 2, D02 VK60, Ireland
    (Address of Principal Executive Offices, including Zip Code)
    Prothena Corporation plc 2018 Long Term Incentive Plan, as amended
    (Full title of the plan)
    Michael J. Malecek
    Chief Legal Officer and Company Secretary
    Prothena Corporation plc
    c/o Prothena Biosciences Inc
    1800 Sierra Point Parkway
    Brisbane, California 94005
    (650) 837-8550 
    (Name, address, including zip code, and telephone number, including area code, of agent for service)



     
     
    Copy to:
    Sharon Flanagan
    Sidley Austin LLP
    555 California Street, Suite 2000
    San Francisco, California 94104
    (415) 772-1271 
     
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filer☒Accelerated filer☐
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
     
     
     



     

    PART I. INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”). This Registration Statement on Form S-8 is filed by Prothena Corporation plc (the “Registrant”) regarding the Prothena Corporation plc 2018 Long Term Incentive Plan, as amended (the “Plan”). Documents containing the information required by Part I of the Registration Statement will be sent or given to participants in the Plan as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).
    PART II. INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE
     
    The information incorporated by reference herein is considered to be part of this Registration Statement, and later information filed with the Commission will update and supersede this information. The following documents filed by the Registrant with the Commission are incorporated herein by reference:
    (a) The Registrant’s Registration Statement on Form 10 (File No. 001-35676) filed with the Commission under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on October 1, 2012, including the description of the Registrant’s ordinary shares contained therein, and any amendment or report filed for the purpose of updating such description, including Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and filed with the Commission on February 27, 2025;
    (b) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 27, 2025;
    (c) The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 8, 2025;
    (d) The Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Commission on August 4, 2025; and
    (e) The Registrant’s Current Reports on Form 8-K filed with the Commission on May 16, 2025, May 23, 2025, June 16, 2025, June 18, 2025, July 30, 2025, and August 6, 2025.
    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the Registration Statement which indicates that all of the ordinary shares offered have been sold or which deregisters all of such shares then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents, except as to any portion of any future annual or quarterly report to shareholders or document or current report furnished under Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.



    ITEM 4. DESCRIPTION OF SECURITIES
    Not applicable.

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL
    Not applicable.

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS
    Under Irish law, a company may not exempt or indemnify its directors from liability for negligence or a breach of duty. However, where a breach of duty has been established, directors may be statutorily exempted by an Irish court from personal liability for negligence or breach of duty if, among other things, the court determines that they have acted honestly and reasonably, and that they may fairly be excused as a result.
    The Irish Companies Act 2014 (the “Companies Act”) permits a company to pay the costs or discharge the liability of a director or the secretary only where judgment is given in his/her favor in any civil or criminal action in respect of such costs or liability, or where an Irish court grants relief because the director or secretary acted honestly and reasonably and ought fairly to be excused. This restriction does not apply to executives who are not directors or the secretary. Any obligation of an Irish company that purports to indemnify a director or secretary of an Irish company over and above this will be void under Irish law, whether contained in its articles of association or any contract between the director or secretary and the company.
    The Registrant’s Amended and Restated Memorandum and Articles of Association (the “Constitution”), which has been publicly filed with the Commission, provides, so far as is permitted under the Companies Act, that every director and the secretary shall be entitled to be indemnified by the Registrant against all costs, charges, losses, expenses and liabilities incurred by him or her in the execution and discharge of his or her duties or in relation thereto including any liability incurred by him or her in defending any proceedings, civil or criminal, which relate to anything done or omitted or alleged to have been done or omitted by him or her as an officer or employee of the Registrant and in which judgement is given in his or her favour (or the proceedings are otherwise disposed of without any finding or admission of any material breach of duty on his or her part) or in which he or she is acquitted or in connection with any application under any statute for relief from liability in respect of any such act or omission in which relief is granted to him or her by the court.
    In addition, the Constitution provides that the Registrant shall indemnify any of its current or former executives (excluding any directors or secretary), or any person who is serving or has served at the Registrant’s request as a director, executive or trustee of another company, joint venture, trust or other enterprise (each, a “Covered Person”), against expenses, including attorneys’ fees, judgements, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with any threatened, pending, or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, to which he or she was, is, or is threatened to be made a party, by reason of the fact that he or she is or was a Covered Person.
    The directors and officers of the Registrant are covered by insurance policies indemnifying against certain liabilities, including certain liabilities arising under the Securities Act, which might be incurred by them in such capacities and against which they may not be indemnified by us.
    The Registrant has also entered into indemnification agreements with each of its directors and executive officers. These agreements, among other things, require the Registrant to indemnify an indemnitee to the fullest extent permitted by applicable law, including indemnification of expenses such as attorneys’ fees, judgments, fines and settlement amounts incurred by the indemnitee in any action or proceeding, arising out of the person’s services as a director or executive officer.
     




    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED
    Not applicable.

    ITEM 8. EXHIBITS
    Exhibit
    Number
    Description
    4.1
    Amended and Restated Memorandum and Articles of Association (Constitution) of Prothena Corporation plc. (1)
    4.2
    Prothena Corporation plc 2018 Long Term Incentive Plan. (2)
    4.3
    First Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan. (3)
    4.4
    Second Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan. (4)
    4.5
    Third Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan. (5)
    4.6
    Fourth Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan. (6)
    4.7
    Fifth Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan. (7)
    4.8
    Sixth Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan. (8) 
    5.1*
    Opinion of A&L Goodbody.
    23.1*
    Consent of KPMG LLP.
    23.2*
    Consent of A&L Goodbody (included in Exhibit 5.1).
    24.1*
    Power of Attorney (included on the signature page hereto).
    107*
    Calculation of Filing Fee Table.
     
    *Filed herewith.

    (1)Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on May 25, 2016.

    (2)Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on May 18, 2018.

    (3)Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on May 22, 2020.

    (4)Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on May 21, 2021.

    (5)Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on May 20, 2022.

    (6)Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on May 19, 2023.

    (7)Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on May 17, 2024.

    (8)Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on May 16, 2025.





    ITEM 9. UNDERTAKINGS
    1. The undersigned registrant hereby undertakes:
    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
    provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference herein.
    (b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    2. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Brisbane, State of California, on this 8th of August, 2025.
     
    PROTHENA CORPORATION PLC
    By:/s/ Gene G. Kinney
    Gene G. Kinney, Ph.D.
    President, Chief Executive Officer and Director



    POWER OF ATTORNEY
    Each person whose signature appears below constitutes and appoints Gene G. Kinney, Tran B. Nguyen and Michael J. Malecek, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including all post-effective amendments), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ Gene G. Kinney
    President, Chief Executive Officer and Director
    (Principal Executive Officer)
    August 8, 2025
    Gene G. Kinney, Ph.D.
    /s/ Tran B. Nguyen
    Chief Strategy Officer and Chief Financial Officer
    (Principal Financial Officer)
    August 8, 2025
    Tran B. Nguyen
    /s/ Karin L. Walker
    Chief Accounting Officer
    (Principal Accounting Officer)
    August 8, 2025
    Karin L. Walker
    /s/ Daniel G. WelchChair of the BoardAugust 8, 2025
    Daniel G. Welch
    /s/ Lars G. Ekman
    Chair Emeritus of the BoardAugust 8, 2025
    Lars G. Ekman, M.D., Ph.D.
    /s/ Paula K. Cobb
    DirectorAugust 8, 2025
    Paula K. Cobb
    /s/ Richard T. Collier
    DirectorAugust 8, 2025
    Richard T. Collier
    /s/ Shane M. Cooke
    DirectorAugust 8, 2025
    Shane M. Cooke
    /s/ William H. Dunn, Jr.
    DirectorAugust 8, 2025
    William H. Dunn, Jr., M.D.
    /s/ Helen S. Kim
    DirectorAugust 8, 2025
    Helen S. Kim
    /s/ Dennis J. SelkoeDirectorAugust 8, 2025
    Dennis J. Selkoe, M.D.


    Get the next $PRTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTA

    DatePrice TargetRatingAnalyst
    5/28/2025$4.00Neutral → Underperform
    BofA Securities
    5/27/2025Outperform → Perform
    Oppenheimer
    5/27/2025$6.00Buy → Hold
    Jefferies
    5/27/2025Overweight → Neutral
    Cantor Fitzgerald
    12/20/2024$40.00Buy
    Chardan Capital Markets
    1/30/2024$68.00 → $38.00Buy → Neutral
    BofA Securities
    12/12/2023$62.00Buy
    Deutsche Bank
    4/24/2023$80.00Outperform
    SVB Securities
    More analyst ratings

    $PRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Zago Wagner M. was granted 85,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:29 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Walker Karin L was granted 25,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:14 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Swanson Chad J. was granted 85,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:01 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

    Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program in 2025 Prothena to earn a clinical milestone payment when prespecified enrollment criteria are met in a Phase 3 clinical trial by Novo Nordisk Prothena Corporation plc (NASDAQ:PRTA), announced that Novo Nordisk communicated during their second quarter 2025 earnings call on August 6, 2025 that they expect to advance coramitug, a potential first-in-class amyloid depleter antibody, into a Phase 3 program for ATTR amyloidosis with cardiomyopathy (A

    8/6/25 9:00:00 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and investing activities was $99.8 million for the first six months of 2025; quarter-end cash and restricted cash position was $372.3 million Prothena expects to convene an Extraordinary General Meeting by year-end 2025 to propose that shareholders approve a reduction of share capital to create distributable reserves in order to support a potential share redemption program if deemed appropriate Roche to advance prasinezumab, a potential first-in-class anti-alpha-synuclein antibody targeting a known biological driver of Parkinson's disease progression, into Phase

    8/4/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena to Report Second Quarter 2025 Financial Results on August 4

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, August 4, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 4. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potent

    7/28/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prothena downgraded by BofA Securities with a new price target

    BofA Securities downgraded Prothena from Neutral to Underperform and set a new price target of $4.00

    5/28/25 8:10:50 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena downgraded by Oppenheimer

    Oppenheimer downgraded Prothena from Outperform to Perform

    5/27/25 9:09:16 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena downgraded by Jefferies with a new price target

    Jefferies downgraded Prothena from Buy to Hold and set a new price target of $6.00

    5/27/25 9:09:16 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Scully William P received a gift of 430,000 units of Ordinary Shares, bought $2,749,916 worth of Ordinary Shares (207,436 units at $13.26) and gifted 747,700 units of Ordinary Shares, decreasing direct ownership by 7% to 735,993 units (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    5/2/25 10:29:05 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

    SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    8/14/25 1:07:20 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

    SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    8/13/25 4:14:07 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Prothena Corporation plc

    S-8 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

    8/8/25 4:30:29 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Leadership Updates

    Live Leadership Updates

    View All

    Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA

    11/12/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports First Quarter 2024 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory

    5/8/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Appoints David Ford to Newly Created Chief People Officer Position

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company's vision and overall growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304692974/en/David Ford, Chief People Officer, Prothena (Photo: Business Wire

    3/4/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Financials

    Live finance-specific insights

    View All

    Prothena to Report Second Quarter 2025 Financial Results on August 4

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, August 4, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 4. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potent

    7/28/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena to Report First Quarter 2025 Financial Results on May 8

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva

    5/1/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

    Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis

    2/20/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/14/24 1:22:34 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/13/24 7:00:50 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/13/24 6:06:27 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care